Chimerix (CMRX)
(Real Time Quote from BATS)
$0.89 USD
-0.04 (-4.54%)
Updated Apr 19, 2024 01:14 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Chimerix, Inc. [CMRX]
Reports for Purchase
Showing records 1 - 20 ( 111 total )
Company: Chimerix, Inc.
Industry: Medical - Products
4Q23 Results; Interim OS Data From the Phase 3 ACTION Study Expected in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
3Q23 Results; Phase 3 ONC201 Data Expected 1H25; Phase 1 ONC206 Safety Data Projected For 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Positive Median Overall Survival Results For ONC201 Published
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
2Q23 Results; Phase 3 ACTION Study Sites Activating at Good Pace; ONC206 Dose Escalation Expected to Complete 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
2Q23 Results; Steadily Advancing Oncology Portfolio Lays Groundwork For Multiple Catalysts in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Chimerix, Inc.
Industry: Medical - Products
Initial Takeaways for Days 1-3 of ASCO 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
1Q23 Results; Phase 3 ACTION Study Efficacy Data in Early-2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
4Q22 Results; Phase 3 ACTION Study Enrolling in the U.S.; Encouraging Response Observed in ONC206 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
ONC201 Update and Workforce Reduction Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E